Effect of Enzyme-containing Lozenge on Dental Biofilm Formation, Composition and Functionality

Sponsor
Novozymes A/S (Industry)
Overall Status
Recruiting
CT.gov ID
NCT06142409
Collaborator
University of Aarhus (Other)
50
1
2
5.5
9.1

Study Details

Study Description

Brief Summary

A double-blind, placebo-controlled randomized cross-over trial evaluating the effect of enzyme-containing lozenge on in vivo and in situ grown dental biofilm accumulation. The study includes two phases, one each for the investigation of in vivo and in situ grown dental biofilm

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Enzyme containing lozenge
N/A

Detailed Description

Up to 50 subjects (aged ≥ 18 years old) with 3 or more active caries lesion, will be randomized to receive:

Phase 1: The effect of multiple-enzyme treatment on plaque accumulation in vivo

Phase 1 includes two experimental periods lasting for one day each, with a washout period of two weeks in between. Each experimental period will include two visits, at day 0 and day 1.

At day 0, the participants will receive a professional tooth cleaning and be randomized to receive Sequence 1 or Sequence 2 in a double-blind randomized cross-over design:

Sequence 1: 3 active enzyme-containing lozenges per day for one day (app. 24h) followed by a washout period of two weeks, followed by 3 identical placebo lozenges per day for one day (app. 24h).

Sequence 2: 3 placebo lozenges per day for one day (app. 24h) followed by a washout period of two weeks, followed by 3 identical active enzyme lozenges per day for one day (app. 24h).

The participants will be instructed to take one lozenge three times (morning, noon, evening) for one day. No normal oral hygiene procedures will be allowed during the intervention periods of one day. At the end of both experimental phases, plaque is assessed using planimetric recordings obtained with an intraoral camera and TM-QHPI to provide information on the individual level of plaque formation.

Phase 2: The effect of multiple-enzyme treatment on in situ-grown biofilms

The phase is designed in a double-blind randomized cross-over design, including two experimental periods lasting for 2 days, with a washout period of 5 days in between. Each experimental period will include two visits, on day 0 and day 2. Oral biofilms will be grown in situ on prefabricated non-fluorescent glass slabs for 48 hours. The glass slabs will be mounted on the individual lower-jaw splints.

At day 0, the participants will be randomized to receive Sequence 1 or Sequence 2:

Sequence 1: 3 active enzyme-containing lozenges per day for 2 days followed by a washout period of 5 days, followed by 3 identical placebo lozenges per day for 2 days.

Sequence 2: 3 placebo lozenges per day for 2 days followed by a washout period of 5 days, followed by 3 identical active enzyme lozenges per day for 2 days.

Oral biofilms will be grown in situ on prefabricated non-fluorescent glass slabs for 2-4 experimental periods of 48 hours. After each experimental period, the in situ-grown biofilms will be collected and stored in a research biobank.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
The Effect of Non-biocidal Adjuncts on the Formation, Composition, Functionality, and Microscale Architecture of Dental Biofilms: a Randomized Controlled Trial
Actual Study Start Date :
Aug 17, 2023
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Feb 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Active arm

Enzyme-containing lozenge

Dietary Supplement: Enzyme containing lozenge
Lozenge containing multiple enzyme combination

Placebo Comparator: Placebo arm

Placebo lozenge

Dietary Supplement: Enzyme containing lozenge
Lozenge containing multiple enzyme combination

Outcome Measures

Primary Outcome Measures

  1. In vivo dental biofilm accumulation [1 day]

    To investigate the effect of an enzyme-containing lozenge on dental biofilm accumulation in caries-active subjects in vivo assessed by the Turesky Modification of the Quigley-Hein Plaque Index (TM-QHPI) and planimetric plaque index

Secondary Outcome Measures

  1. in situ grown dental biofilm accumulation [2 days]

    To assess the effect of enzyme-containing lozenge on the microarchitecture and metabolism of in situ-grown biofilms from caries-active subjects analyzed by optical coherence tomography.

  2. Characterization of in situ grown dental biofilm [2 days]

    To characterize the microstructure, composition, and functionality of in situ-grown biofilms from caries-active subjects. Microbial DNA extraction, and next-generation sequencing of 16S rRNA genes and selected functional genes will be performed to investigate the shift in oral microbial community composition, diversity, and functionality.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Males and females ≥ 18 years old.

  • Have three or more active carious lesions.

  • Anatomically possible to manufacture an intraoral lower-jaw splint.

  • Able to understand and follow instructions, as well as to read and sign the informed consent form.

  • A plaque index score ≥ 2 according to the Turesky Modification of the Quigley-Hein Plaque Index (TM-QHPI), following 8 to 12 hours plaque accumulation period.

Exclusion Criteria:
  • History of allergies towards any of the ingredients in the test products

  • Self-reported pregnant or nursing

  • Antibiotic or anti-inflammatory medication within 90 days of the screening visit.

  • Orthodontic appliances, including retainers, or removable partial dentures.

  • Self-reported serious medical conditions

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Dentistry and Oral Health, Aarhus University Aarhus Denmark DK-8000 Aarhus C

Sponsors and Collaborators

  • Novozymes A/S
  • University of Aarhus

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Novozymes A/S
ClinicalTrials.gov Identifier:
NCT06142409
Other Study ID Numbers:
  • NZ-2022-05
First Posted:
Nov 21, 2023
Last Update Posted:
Nov 21, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 21, 2023